Beneficient (NASDAQ:BENF) Director Peter T. Cangany, Jr. Buys 75,000 Shares of Stock

Beneficient (NASDAQ:BENFGet Free Report) Director Peter T. Cangany, Jr. acquired 75,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $0.93 per share, with a total value of $69,750.00. Following the completion of the purchase, the director now directly owns 300,000 shares of the company’s stock, valued at approximately $279,000. This represents a 33.33 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Beneficient Trading Down 9.0 %

Shares of Beneficient stock opened at $0.82 on Thursday. Beneficient has a 12-month low of $0.72 and a 12-month high of $51.14. The company has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $2.43.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Beneficient stock. Stifel Financial Corp raised its holdings in Beneficient (NASDAQ:BENFFree Report) by 138.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,300 shares of the company’s stock after purchasing an additional 14,100 shares during the quarter. Stifel Financial Corp owned approximately 0.57% of Beneficient worth $30,000 as of its most recent SEC filing. Institutional investors and hedge funds own 90.57% of the company’s stock.

Beneficient Company Profile

(Get Free Report)

Beneficient, a technology-enabled financial services company, provides liquidity solutions and related trustee, custody and trust administrative services to participants in the alternative asset industry in the United States. It operates through Ben Liquidity, Ben Custody, and Customer ExAlt Trusts segments.

See Also

Insider Buying and Selling by Quarter for Beneficient (NASDAQ:BENF)

Receive News & Ratings for Beneficient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beneficient and related companies with MarketBeat.com's FREE daily email newsletter.